No Data
No Data
Express News | Revelation Biosciences Doses First Patient in Prime Phase 1B Clinical Study of Gemini in Ckd Patients
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences Advances PRIME Phase 1b Trial for Chronic Kidney Disease Treatment, Maintains Nasdaq Listing, Meets All Compliance Requirements
Express News | Revelation Biosciences, Inc. Receives Continued Nasdaq Listing Approval
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
Express News | Watching Revelation Bios; Zacks Small-Cap Research Gives Stock $21.45 Price Valuation